MKGAF (Merck KGaA) Long-Term Debt: $0 Mil (As of Mar. 2026)


MKGAF Merck KGaA MKGAF
84 GF Score
Price $164.15
GF Value $159.56
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Long-Term Debt?

Merck KGaA MKGAF +1.82% 84 Long-Term Debt is $0 Mil as of Mar. 2026. GuruFocus rates MKGAF with a GF Score™ of 84/100 and a GF Value™ of $159.56 (Fairly Valued). The stock has 10 warning signs investors should review.

Merck KGaA's Long-Term Debt for the quarter that ended in Mar. 2026 was $0 Mil.

Merck KGaA's quarterly Long-Term Debt increased from Sep. 2025 ($0 Mil) to Dec. 2025 ($11,951 Mil) but then declined from Dec. 2025 ($11,951 Mil) to Mar. 2026 ($0 Mil).

Merck KGaA's annual Long-Term Debt declined from Dec. 2023 ($9,647 Mil) to Dec. 2024 ($6,673 Mil) but then increased from Dec. 2024 ($6,673 Mil) to Dec. 2025 ($11,951 Mil).

Merck KGaA  (OTCPK:MKGAF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Merck KGaA Long-Term Debt Related Terms

Merck KGaA Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Long-Term Debt Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,958.19 9,358.05 9,646.67 6,673.30 11,950.82

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 11,950.82 0.00
MKGAF
84GF Score
Merck KGaA MKGAF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0 Mil mean?
Merck KGaA (MKGAF) has a Long-Term Debt of $0 Mil as of Mar. 2026.
Is Merck KGaA's Long-Term Debt too high?
Merck KGaA's current Long-Term Debt is $0 Mil. Overall, Merck KGaA has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Long-Term Debt compare to ZTS and UTHR?
Merck KGaA's Long-Term Debt of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Merck KGaA's current Long-Term Debt is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (MKGAF) is currently considered Fairly Valued. The stock's GF Value™ is $159.56, compared to a current price of $164.15 — trading 2.9% above its estimated fair value. The current Long-Term Debt is $0 Mil. Merck KGaA's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Merck KGaA (MKGAF), the current Long-Term Debt is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (MKGAF) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of $164.15 is trading 2.9% above its estimated GF Value™ of $159.56. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for MKGAF:

  • Long-Term Debt: $0 Mil
  • GF Value™: $159.56 vs. price of $164.15 (2.9% above fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the MKGAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score

Get the complete analysis for MKGAF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$164.15
Price
$159.56
GF Value